Stock FLAG.U FIRST LIGHT ACQUISITION GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

First Light Acquisition Group, Inc. Stock Nyse

Equities

FLAG.U

US3207032000

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 5.69M
Net income 2024 * -40M Net income 2025 * -42M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.16 x
P/E ratio 2025 *
-0.25 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data

Chart First Light Acquisition Group, Inc.

Dynamic Chart

Latest news about First Light Acquisition Group, Inc.

Calidi Biotherapeutics Prices $6.1 Million Offering MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding CI
Sector Update: Health Care Stocks Firmer Late Afternoon MT
Calidi Biotherapeutics to Sell Common Stock MT
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding CI
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments CI
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index CI
Calidi Biotherapeutics Announces Directorate Changes CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $25 million in funding from Yorkville Advisors Global LP CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board CI
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target MT
Calidi Biotherapeutics Gets US Patent for Cancer Treatment Technology Platform MT
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting CI
More news

Analyst Recommendations on First Light Acquisition Group, Inc.

Calidi Biotherapeutics Prices $6.1 Million Offering MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target MT
Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9 MT
More recommendations

Press releases First Light Acquisition Group, Inc.

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering BU
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024 AQ
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024 BU
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results BU
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer BU
More press releases

Company Profile

First Light Acquisition Group, Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its efforts on identifying prospective opportunities that provide technology-enabled solutions with high-growth, mission-critical applications in government and commercial markets. The Company is not engaged in any business operations and has not generated any revenue.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. FLAG.U Stock